Safety and Efficacy ofLutetium-PSMA-617 Radioligand Therapy Shortly after FailingRadium-Dichloride.
Baumgarten Justus, Groener Daniel, Nguyen Ngoc Christina, +9 more·Cancers
Bone-seekingRadium-dichloride (Ra) is an established treatment prolonging survival and reducing morbidity in selected patients with metastatic castration-resistant prostate cancer (mCRPC) with skeletal involvement. Radioligand therapy withLutetium-PSMA-617 (Lu-PSMA-617) has been increasingly implemented in patients wit…